New P2Y12Inhibitors Versus Clopidogrel in Percutaneous Coronary Intervention
Authors:
- David BriegerDBDavid Brieger
- Farzin BeyguiFBFarzin Beygui
- Johanne SilvainJSJohanne Silvain
- Ana PenaAPAna Pena
- Guillaume CaylaGCGuillaume Cayla
- Olivier BarthélémyOBOlivier Barthélémy
- Jean-Philippe ColletJCJean-Philippe Collet
- Gilles MontalescotGMGilles Montalescot
- 1 November 2010
- Vol. 56 (19) , 1542-1551
Abstract
No abstract availableKeywords
Funding Information
- Sanofi-Aventis
- Eli Lilly
- Merck/Schering Plough
- National Heart Foundation of Australia
- Sanofi-Aventis
- Daiichi-Sankyo
- Eli Lilly
- Inserm
- Fédération Française de Cardiologie
- Société Française de Cardiologie
- Fédération Française de Cardiologie
- Bristol-Myers Squibb
- Sanofi-Aventis
- Eli Lilly
- Guerbet Medical
- Medtronic
- Boston Scientific
- Cordis
- Stago
- Centocor
- Fondation de France
- Inserm
- Fédération Française de Cardiologie
- Société Française de Cardiologie
- Sanofi-Aventis
- Eli Lilly
- Bristol-Myers Squibb
- Bristol-Myers Squibb
- Sanofi-Aventis
- Eli Lilly
- Guerbet Medical
- Medtronic
- Boston Scientific
- Cordis
- Stago
- Centocor
- Fondation de France
- Inserm
- Fédération Française de Cardiologie
- Société Française de Cardiologie
This publication has 29 references indexed in Scilit:
- Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind studyThe Lancet, 2010
- Intravenous Platelet Blockade with Cangrelor during PCINew England Journal of Medicine, 2009
- Platelet Inhibition with Cangrelor in Patients Undergoing PCINew England Journal of Medicine, 2009
- Safety and feasibility of adjunctive antiplatelet therapy with intravenous elinogrel, a direct-acting and reversible P2Y12 ADP-receptor antagonist, before primary percutaneous intervention in patients with ST-elevation myocardial infarction: The Early Rapid ReversAl of Platelet ThromboSis with Intravenous Elinogrel before PCI to Optimize REperfusion in Acute Myocardial Infarction (ERASE MI) pilot trialAmerican Heart Journal, 2009
- Association of Cytochrome P450 2C19 Genotype With the Antiplatelet Effect and Clinical Efficacy of Clopidogrel TherapyJAMA, 2009
- Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trialThe Lancet, 2009
- Cytochrome P-450 Polymorphisms and Response to ClopidogrelNew England Journal of Medicine, 2009
- Genetic Determinants of Response to Clopidogrel and Cardiovascular EventsNew England Journal of Medicine, 2009
- Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort studyThe Lancet, 2009
- Prasugrel versus Clopidogrel in Patients with Acute Coronary SyndromesNew England Journal of Medicine, 2007